1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Drs. Aird, Neuberg, Thompson, and Shulman as well as Ms. MacNeill also are affiliated with the Dana-Farber Cancer Institute, Boston, Massachusetts.
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine
A pharmacologically based regimen
Article first published online: 20 NOV 2000
DOI: 10.1002/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K
Copyright © 2000 American Cancer Society
Additional Information
How to Cite
Sternberg, D. W., Aird, W., Neuberg, D., Thompson, L., MacNeill, K., Amrein, P. and Shulman, L. N. (2000), Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine. Cancer, 88: 2037–2041. doi: 10.1002/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K
Publication History
- Issue published online: 20 NOV 2000
- Article first published online: 20 NOV 2000
- Manuscript Accepted: 13 JAN 2000
- Manuscript Received: 9 NOV 1999
- Abstract
- Article
- References
- Cited By
Keywords:
- acute myelogenous leukemia;
- Ara-C;
- mitoxantrone;
- disease remission
Patients with recurrent or refractory acute myelogenous leukemia were treated with intermediate-dose cytarabine, 500 mg/m2, every 12 hours × 12 doses, and mitoxantrone, 5 mg/m2/day × 5 days. The complete remission rate for these patients was 62% and the regimen was well tolerated, including in elderly patients.
Abstract
BACKGROUND
Although chemotherapy can achieve a high rate of disease remission induction in patients with newly diagnosed acute myelogenous leukemia (AML), patients with recurrent or refractory AML generally have a poorer rate of response. This study assessed the utility of mitoxantrone and intermediate-dose cytarabine (Ara-C) in the treatment of patients with recurrent or refractory AML.
METHODS
Forty-seven patients with recurrent or refractory AML were treated with Ara-C, 0.5 gm/m2, intravenously (i.v.) every 12 hours × 12 doses on Days 1–6 and mitoxantrone, 5 mg/m2, i.v. on Days 1–5.
RESULTS
Twenty-nine of the 47 patients (62%) achieved a complete response. The median duration of disease remission was 112 days (range, 29 days–8 years). Of the 25 patients age ≥ 60 years, 19 (76%) had a complete disease remission and the median duration of disease remission in this group was 114 days (range, 33–370 days), although all patients subsequently developed a disease recurrence. The chemotherapy generally was well tolerated, with a mean duration of neutropenia of 31 days and a mean duration of thrombocytopenia of 33 days. Three patients died of infectious complications between 23–26 days after the initiation of chemotherapy, 1 patient died of sudden cardiac arrest 13 days after the initiation of chemotherapy, and 1 patient developed cutaneous desquamation. Three patients developed acute cerebellar dysfunction.
CONCLUSIONS
The use of mitoxantrone and Ara-C is effective in the treatment of patients with recurrent and refractory AML. The subgroup of patients age ≥ 60 years also had a high rate of disease remission induction with this regimen, and the regimen generally was well tolerated. Cancer 2000;88:2037–41. © 2000 American Cancer Society.